Member Info for miavoce

A sure fire way to put off new small investors is to have a BB that is overwhelmed by bickering. Whoever set out to achieve this has done a great job.

Trump has higher favourability ratings (by 3-4 points) than at any time in his first term. Lets see how things pan out.

I can only see one delayed trade sell (500k after hours) and a 625k buy from this morning before the buy price rose from 9.8 to 10.

'I know my outlook towards how this is panning out is very grim. Seems we’re getting nowhere fast'

Once our seller has finished killing every attempt at a rise things will change.

Who will rid me of this turbulent after hours seller !

That's the spirit Angelo !

Done and dusted Rigga. Was oversubscribed by 70%.

Circa 70% oversubscribed i.e. for each available 59 shares 100 shares were requested.

Hi BeardedDragon

just so as you know, Scinv_temp has tendency to call people fools, don't take it personally.

Bermudashorts - they have applied to MHRA....

Incidentally I have suggested to LD that they update the market by some means regarding cohort 4 - I think it would help and I hope that they do so.

Not sure if adds to the conversation but LD has confirmed 'we decided to do this [cohort 4] as the recent lab data suggests that iscib1+ was better when given intradermal rather than intramuscular. '

Note the word 'recent'.

Hi emptyend

I had made the same guess about the Genmab timing 3 hours earlier than your good self - not that I'm competitive :-)

Hi all

having been in touch with LD I can confirm that they were indeed surprised by the Genmab timing (they expected the decision a month later) and that it was unfortunate that it coincided exactly with the fundraise.

The early decision by Genmab is clearly a good thing.

The fundraise would have been planned for yesterday a good while in advance. I suspect that they were taken by surprise by Genmab agreeing the deal so early in December and on the exact day of the fundraise, which was obviously outside Scancell's control.

Why didn't Scancell plan their fundraise for Jan, by which time the Genmab decision would have been known ? Well, imagine if Genmab had decided not to progress with the deal, what price do you think the fundraise would have achieved then ?

Ultimately Scancell had to decide whether to do the fundraise before or after the Genmab decision, and they went for the safe option to do it before. Unfortunately they then got caught out by Genmab making their decision at the same time as the fundraise.

All IMO but makes perfect sense when you look back at what happened.

One benefit of the Genmab decision landing on the same day as the fundraise is that it must have increased support for the fundraise.

The fall is largely for technical reasons. If the price was meaningfully above the offer price (e.g 12p) then those taking part in the offer could simply forward sell for 12p the shares they are buying in the offer at 10.5p and make an instant profit. Therefore on the day of the offer the shareprice quickly moves towards the offer price. Also, many shareholders are aware that the share price will quickly move to the offer price and so they look to sell before that happens, which again drives the share price towards the offer price. It will settle down in the next days / weeks and will return to the 'correct' level as bargain hunters utilise the buying opportunity.

Hi Stakis - I bought more than I thought I would be able to get in the open offer without getting scaled back. I may turn out to be wrong but I didn't want to take that risk.

This fundraise is simply one of the necessary evils when investing in a small biotech on AIM. They always come as a surprise, they are always painful in the short term, and we always feel that we have been in some way deceived by the BOD. This is just how it is.

The reality however is that this fundraise is fairly small and significantly strengthens the company's ability to deliver against its goals and to create shareholder value. In the weeks to come I expect that this reality will be reflected in the share price which is why I bough more this morning at what I believe is the bargain price of just over 10.7p.

CrustyPete - the next Genmab milestone on the first deal will be a few million, not enough to fund the co. hence this additional relatively small fundraise (existing cash + Genmab2 payment + fundraise + likely Genmab1 milestone funds the co. well into 2026).

The left field funding option is a very good deal on the 'crown jewel' SC134....may not cover the full cost of the registration trial but could make a decent sized dent in it.